JP5328357B2 - 化学放射線増感剤としてのカンプトテシン誘導体 - Google Patents

化学放射線増感剤としてのカンプトテシン誘導体 Download PDF

Info

Publication number
JP5328357B2
JP5328357B2 JP2008536850A JP2008536850A JP5328357B2 JP 5328357 B2 JP5328357 B2 JP 5328357B2 JP 2008536850 A JP2008536850 A JP 2008536850A JP 2008536850 A JP2008536850 A JP 2008536850A JP 5328357 B2 JP5328357 B2 JP 5328357B2
Authority
JP
Japan
Prior art keywords
cpt
hydroxy
lower alkyl
amino
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008536850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009512714A5 (cg-RX-API-DMAC7.html
JP2009512714A (ja
Inventor
リ−シ・ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catholic Healthcare West
Sutter West Bay Hospitals
Original Assignee
Catholic Healthcare West
Sutter West Bay Hospitals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catholic Healthcare West, Sutter West Bay Hospitals filed Critical Catholic Healthcare West
Publication of JP2009512714A publication Critical patent/JP2009512714A/ja
Publication of JP2009512714A5 publication Critical patent/JP2009512714A5/ja
Application granted granted Critical
Publication of JP5328357B2 publication Critical patent/JP5328357B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2008536850A 2005-10-21 2006-10-19 化学放射線増感剤としてのカンプトテシン誘導体 Expired - Fee Related JP5328357B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72892405P 2005-10-21 2005-10-21
US60/728,924 2005-10-21
US11/444,150 US7875602B2 (en) 2005-10-21 2006-05-30 Camptothecin derivatives as chemoradiosensitizing agents
US11/444,150 2006-05-30
PCT/US2006/041175 WO2007048002A2 (en) 2005-10-21 2006-10-19 Camptothecin derivatives as chemoradiosensitizing agents

Publications (3)

Publication Number Publication Date
JP2009512714A JP2009512714A (ja) 2009-03-26
JP2009512714A5 JP2009512714A5 (cg-RX-API-DMAC7.html) 2009-12-03
JP5328357B2 true JP5328357B2 (ja) 2013-10-30

Family

ID=37963356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008536850A Expired - Fee Related JP5328357B2 (ja) 2005-10-21 2006-10-19 化学放射線増感剤としてのカンプトテシン誘導体

Country Status (11)

Country Link
US (3) US7875602B2 (cg-RX-API-DMAC7.html)
EP (1) EP1951231B1 (cg-RX-API-DMAC7.html)
JP (1) JP5328357B2 (cg-RX-API-DMAC7.html)
KR (1) KR101320160B1 (cg-RX-API-DMAC7.html)
CN (1) CN101300009B (cg-RX-API-DMAC7.html)
AU (1) AU2006304811C1 (cg-RX-API-DMAC7.html)
CA (1) CA2626032C (cg-RX-API-DMAC7.html)
ES (1) ES2428088T3 (cg-RX-API-DMAC7.html)
NZ (2) NZ593706A (cg-RX-API-DMAC7.html)
TW (1) TWI402270B (cg-RX-API-DMAC7.html)
WO (1) WO2007048002A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10046022B2 (en) 2015-05-29 2018-08-14 Toagosei Co. Ltd. Synthetic peptide that increases radiosensitivity of tumor cells and use of same
US10981953B2 (en) 2013-12-26 2021-04-20 Toagosei Co, Ltd. Method for promoting expression of calreticulin, and synthetic peptide for use in method for promoting expression of calreticulin

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101402640B (zh) * 2008-09-02 2011-06-15 暨南大学 双酯化喜树碱衍生物及其制备方法和应用
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
US8168648B2 (en) * 2009-03-06 2012-05-01 Taiwan Liposome Co., Ltd. Camptothecin derivatives and uses thereof
EP2443125B1 (en) * 2009-06-17 2014-11-26 Threshold Pharmaceuticals, Inc. Camptothecin derivatives
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
TWI619496B (zh) 2011-11-03 2018-04-01 台灣微脂體股份有限公司 疏水性喜樹鹼衍生物之醫藥組合物
US20140135357A1 (en) * 2012-11-12 2014-05-15 Taiwan Liposome Company, Ltd. Dose regime for camptothecin derivatives
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US10087194B2 (en) 2015-10-27 2018-10-02 California Pacific Medical Center Podophyllotoxin derivatives and their use
CN106937529B (zh) * 2015-10-27 2021-02-05 加州太平洋医疗中心 鬼臼毒素衍生物及其应用
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
AU2020309244A1 (en) 2019-07-11 2022-03-03 Sun Pharma Advanced Research Company Ltd. Camptothecin derivatives with a disulfide moiety and a piperazine moiety
WO2021154746A1 (en) 2020-01-28 2021-08-05 Reflexion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US554990A (en) * 1896-02-18 Target-throwing trap
US4399282A (en) 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5196413A (en) 1984-12-10 1993-03-23 Johnson Matthey, Inc. Platinum complexes and the like
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5175278A (en) 1985-06-28 1992-12-29 Merck & Co., Inc. Heteropolysaccharide S-657
US4727068A (en) 1985-10-23 1988-02-23 Johnson Matthey, Inc. Radiosensitization by cobalt and Fe(III) complexes
US5175287A (en) 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US4921963A (en) 1987-04-13 1990-05-01 British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
US5026694A (en) 1987-04-13 1991-06-25 The British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
US5304654A (en) 1987-06-10 1994-04-19 Yasunori Nishijima Fluorine-containing nitroimidazole compounds
CA1329206C (en) 1987-06-10 1994-05-03 Tsutomu Kagiya Fluorine-containing nitroazole derivatives and radiosensitizer comprising the same
US4797397A (en) 1987-07-31 1989-01-10 Warner-Lambert Company 2-nitroimidazole derivatives useful as radiosensitizers for hypoxic tumor cells
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
JPH0819111B2 (ja) 1987-10-22 1996-02-28 ポーラ化成工業株式会社 2―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤
US5036096A (en) 1988-11-25 1991-07-30 Warner-Lambert Company Aziridino derivatives of nitroimidazoles and pharmaceutical compositions of selected derivatives
US4954515A (en) 1988-11-25 1990-09-04 Warner-Lambert Company Haloalkylaminomethyl-2-nitro-1H-imidazoles
US5043165A (en) 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
IL92597A0 (en) 1988-12-14 1990-08-31 Yasunori Nishijima President K Novel fluorine-containing 2-nitroimidazole derivatives and radiosensitizer comprising the same
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5294715A (en) 1991-02-01 1994-03-15 University Of Pittsburgh Acridine-intercalator based hypoxia selective cytotoxins
CA2097163C (en) 1992-06-01 2002-07-30 Marianna Foldvari Topical patch for liposomal drug delivery system
MX9304399A (es) 1992-07-31 1994-02-28 Warner Lambert Co Proceso novedoso para preparar [[2-bromoetil)-amino]metil]-2-nitro-1h-imidazol-1-etanol quiral y compuestos relacionados.
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5646159A (en) 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
GB9504065D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Poly-pyrrolecarboxamidonaphthalenic acid derivatives
US5736156A (en) 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US6060604A (en) 1995-03-31 2000-05-09 Florida State University Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups
JPH08333370A (ja) 1995-06-08 1996-12-17 Kyorin Pharmaceut Co Ltd 水に可溶な新規フルオロエチルカンプトテシン誘導体、及びその製造方法
GB9512670D0 (en) 1995-06-21 1995-08-23 Sod Conseils Rech Applic Camptothecin analogues
US6339091B1 (en) 1995-06-21 2002-01-15 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Comptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues
CN1211919A (zh) 1995-09-13 1999-03-24 佛罗里达州立大学 放射增敏性紫杉烷及其药物制剂
WO1997019085A1 (en) 1995-11-22 1997-05-29 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6096336A (en) 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US5874105A (en) 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
DE69728152T2 (de) 1996-08-19 2004-08-05 Bionumerik Pharmaceuticals, Inc., San Antonio Hoch-lipophile campothecin-derivate
AU4424797A (en) 1996-09-18 1998-04-14 Dragoco Inc. Liposome encapsulated active agent dry powder composition
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998014459A1 (de) 1996-09-30 1998-04-09 Bayer Aktiengesellschaft Glycokonjugate von modifizierten camptothecin-derivaten (20-o-verknüpfung)
KR100219562B1 (ko) * 1996-10-28 1999-09-01 윤종용 반도체장치의 다층 배선 형성방법
SG88737A1 (en) 1996-10-30 2002-05-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
DE69834923T2 (de) 1997-02-14 2006-10-19 Bionumerik Pharmaceuticals, Inc., San Antonio Hochgradig lipophile camptothecin-derivate
JP3209509B2 (ja) * 1997-03-28 2001-09-17 インターナショナル・ビジネス・マシーンズ・コーポレーション ディスク状記録装置及びディスクドライブ装置
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
GB9721070D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
US5935949A (en) 1998-03-20 1999-08-10 Trustees Of Dartmouth College Use of androgen therapy in fibromyalgia and chronic fatigue syndrome
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6057303A (en) 1998-10-20 2000-05-02 Bionumerik Pharmaceuticals, Inc. Highly lipophilic Camptothecin derivatives
US6207832B1 (en) 1999-04-09 2001-03-27 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US6281223B1 (en) 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
AU4822500A (en) 1999-05-04 2000-11-17 Bionumerik Pharmaceuticals, Inc. Novel highly lipophilic camptothecin analogs
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
US6228855B1 (en) * 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
CA2391534A1 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US6423707B1 (en) 2000-08-28 2002-07-23 California Pacific Medical Center Nitroimidazole ester analogues and therapeutic applications
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
GB0119578D0 (en) 2001-08-10 2001-10-03 Pharmacia & Upjohn Spa Fluoro linkers
US6933302B2 (en) 2002-06-03 2005-08-23 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981953B2 (en) 2013-12-26 2021-04-20 Toagosei Co, Ltd. Method for promoting expression of calreticulin, and synthetic peptide for use in method for promoting expression of calreticulin
US10046022B2 (en) 2015-05-29 2018-08-14 Toagosei Co. Ltd. Synthetic peptide that increases radiosensitivity of tumor cells and use of same

Also Published As

Publication number Publication date
US8563537B2 (en) 2013-10-22
AU2006304811A1 (en) 2007-04-26
HK1115321A1 (en) 2008-11-28
AU2006304811B2 (en) 2012-03-22
US8779138B2 (en) 2014-07-15
CN101300009B (zh) 2013-04-03
JP2009512714A (ja) 2009-03-26
US20110184009A1 (en) 2011-07-28
KR101320160B1 (ko) 2013-10-23
KR20080086436A (ko) 2008-09-25
EP1951231A2 (en) 2008-08-06
TWI402270B (zh) 2013-07-21
EP1951231B1 (en) 2013-07-31
EP1951231A4 (en) 2010-09-22
US20070093432A1 (en) 2007-04-26
AU2006304811C1 (en) 2012-11-01
WO2007048002A3 (en) 2007-09-13
WO2007048002A2 (en) 2007-04-26
CA2626032A1 (en) 2007-04-26
TW200730532A (en) 2007-08-16
US7875602B2 (en) 2011-01-25
US20080318873A1 (en) 2008-12-25
CA2626032C (en) 2011-12-06
CN101300009A (zh) 2008-11-05
ES2428088T3 (es) 2013-11-05
NZ593706A (en) 2012-11-30
NZ567454A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
US8779138B2 (en) Camptothecin derivatives as chemoradiosensitizing agents
KR101688898B1 (ko) 소수성 캄프토테신 유도체의 약제 조성물
JP4243484B2 (ja) カンプトテシン誘導体
CN113230417B (zh) 葡萄糖和三苯基鏻修饰的脑肿瘤靶向脂质体的制备与应用
CN110981870A (zh) 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途
JP2009512714A5 (cg-RX-API-DMAC7.html)
Takasu et al. Synthesis and evaluation of β-carbolinium cations as new antimalarial agents based on π-delocalized lipophilic cation (DLC) hypothesis
CN101328159B (zh) 紫杉烷前体抗癌药及其药物组合物和用途
EP2205605B1 (en) Hydrated crystalline esters of camptothecin for the treatment of cancer
HK1115321B (en) Camptothecin derivatives as chemoradiosensitizing agents
WO2010042600A2 (en) Photo-activatable therapeutic agents and methods of using
CA2518748A1 (en) Antimicrobial agents and anticancer agents
CN101402640B (zh) 双酯化喜树碱衍生物及其制备方法和应用
US8071760B2 (en) Boron-containing porphyrin compounds and their uses
US9321781B2 (en) Topoisomerase inhibitors
CN119424638A (zh) 一种乏氧加速药物释放的纳米诊疗制剂及其制备方法
HK1196556A (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
NZ620933B2 (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
HK1196556B (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130723

R150 Certificate of patent or registration of utility model

Ref document number: 5328357

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees